542 related articles for article (PubMed ID: 16567356)
1. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
[TBL] [Abstract][Full Text] [Related]
4. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
5. Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes.
Mou YK; Zhang PP; Li QX; Lin ZM; Liao ZT; Wei QJ; Gu JR
Clin Rheumatol; 2015 Jun; 34(6):1085-9. PubMed ID: 25912212
[TBL] [Abstract][Full Text] [Related]
6. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
7. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
[TBL] [Abstract][Full Text] [Related]
8. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.
Chen CH; Chen HA; Liao HT; Liu CH; Tsai CY; Chou CT
Clin Rheumatol; 2010 Oct; 29(10):1155-61. PubMed ID: 20690034
[TBL] [Abstract][Full Text] [Related]
9. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
Franck H; Meurer T; Hofbauer LC
J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
[TBL] [Abstract][Full Text] [Related]
11. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
[TBL] [Abstract][Full Text] [Related]
12. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of osteoporosis and vertebral fractures and related factors in patients with ankylosing spondylitis.
Ulu MA; Batmaz İ; Dilek B; Çevik R
Chin Med J (Engl); 2014; 127(15):2740-7. PubMed ID: 25146606
[TBL] [Abstract][Full Text] [Related]
15. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
[TBL] [Abstract][Full Text] [Related]
16. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
18. The Role of Tumor Necrosis Factor Alpha and TNF Superfamily Members in Bone Damage in Patients with End-Stage Chronic Obstructive Lung Disease Prior to Lung Transplantation.
Kochetkova EA; Nevzorova VA; Ugai LG; Maistrovskaia YV; Massard G
Calcif Tissue Int; 2016 Dec; 99(6):578-587. PubMed ID: 27501819
[TBL] [Abstract][Full Text] [Related]
19. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
[TBL] [Abstract][Full Text] [Related]
20. Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study.
Jun JB; Joo KB; Her MY; Kim TH; Bae SC; Yoo DH; Kim SK
J Rheumatol; 2006 Aug; 33(8):1637-41. PubMed ID: 16881119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]